Cargando…
Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
This study aimed to investigate the impact of indoleamine 2,3-dioxygenase 1 (IDO1) expression, programmed cell death-ligand 1 (PD-L1) expression, CD8+ tumor-infiltrating lymphocyte (TIL) status, and their combination on pathologic complete response (pCR) and recurrence in esophageal squamous cell ca...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406509/ https://www.ncbi.nlm.nih.gov/pubmed/30717285 http://dx.doi.org/10.3390/cancers11020169 |
_version_ | 1783401321912598528 |
---|---|
author | Zhou, Sha Zhao, Lei Liang, Zhaohui Liu, Songran Li, Yong Liu, Shiliang Yang, Hong Liu, Mengzhong Xi, Mian |
author_facet | Zhou, Sha Zhao, Lei Liang, Zhaohui Liu, Songran Li, Yong Liu, Shiliang Yang, Hong Liu, Mengzhong Xi, Mian |
author_sort | Zhou, Sha |
collection | PubMed |
description | This study aimed to investigate the impact of indoleamine 2,3-dioxygenase 1 (IDO1) expression, programmed cell death-ligand 1 (PD-L1) expression, CD8+ tumor-infiltrating lymphocyte (TIL) status, and their combination on pathologic complete response (pCR) and recurrence in esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (CRT). Indoleamine 2,3-dioxygenase 1, PD-L1, and CD8+ TIL statuses were evaluated by immunohistochemical analysis on pre-CRT biopsies of 158 patients. Sixty-eight patients (43.0%) achieved pCR after neoadjuvant CRT and 48 patients (30.4%) developed recurrences after surgery. IDO1 and PD-L1 proteins were co-expressed in 28 patients (17.7%). Indoleamine 2,3-dioxygenase 1 positive patients showed a significantly lower pCR rate than IDO1 negative patients (28.6% vs. 51.0%, P = 0.007). Similarly, PD-L1 high expression was significantly negatively correlated with pCR rate (27.3% vs. 51.5%, P = 0.004). On multivariate analysis, IDO1 expression was an independent prognostic factor for developing recurrences. Stratification analysis revealed that patients with co-expression of IDO1 and PD-L1 were significantly associated with a lower pCR rate and worse recurrence-free survival than those with one or none positive protein. In conclusion, IDO1 and PD-L1 co-expression could predict poor pathologic response and high risk of recurrence in ESCC after neoadjuvant CRT, indicating a subset of patients who may benefit from CRT combined with immunotherapy. |
format | Online Article Text |
id | pubmed-6406509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64065092019-03-21 Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy Zhou, Sha Zhao, Lei Liang, Zhaohui Liu, Songran Li, Yong Liu, Shiliang Yang, Hong Liu, Mengzhong Xi, Mian Cancers (Basel) Article This study aimed to investigate the impact of indoleamine 2,3-dioxygenase 1 (IDO1) expression, programmed cell death-ligand 1 (PD-L1) expression, CD8+ tumor-infiltrating lymphocyte (TIL) status, and their combination on pathologic complete response (pCR) and recurrence in esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (CRT). Indoleamine 2,3-dioxygenase 1, PD-L1, and CD8+ TIL statuses were evaluated by immunohistochemical analysis on pre-CRT biopsies of 158 patients. Sixty-eight patients (43.0%) achieved pCR after neoadjuvant CRT and 48 patients (30.4%) developed recurrences after surgery. IDO1 and PD-L1 proteins were co-expressed in 28 patients (17.7%). Indoleamine 2,3-dioxygenase 1 positive patients showed a significantly lower pCR rate than IDO1 negative patients (28.6% vs. 51.0%, P = 0.007). Similarly, PD-L1 high expression was significantly negatively correlated with pCR rate (27.3% vs. 51.5%, P = 0.004). On multivariate analysis, IDO1 expression was an independent prognostic factor for developing recurrences. Stratification analysis revealed that patients with co-expression of IDO1 and PD-L1 were significantly associated with a lower pCR rate and worse recurrence-free survival than those with one or none positive protein. In conclusion, IDO1 and PD-L1 co-expression could predict poor pathologic response and high risk of recurrence in ESCC after neoadjuvant CRT, indicating a subset of patients who may benefit from CRT combined with immunotherapy. MDPI 2019-02-01 /pmc/articles/PMC6406509/ /pubmed/30717285 http://dx.doi.org/10.3390/cancers11020169 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhou, Sha Zhao, Lei Liang, Zhaohui Liu, Songran Li, Yong Liu, Shiliang Yang, Hong Liu, Mengzhong Xi, Mian Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy |
title | Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy |
title_full | Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy |
title_fullStr | Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy |
title_full_unstemmed | Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy |
title_short | Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy |
title_sort | indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression predicts poor pathologic response and recurrence in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406509/ https://www.ncbi.nlm.nih.gov/pubmed/30717285 http://dx.doi.org/10.3390/cancers11020169 |
work_keys_str_mv | AT zhousha indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy AT zhaolei indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy AT liangzhaohui indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy AT liusongran indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy AT liyong indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy AT liushiliang indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy AT yanghong indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy AT liumengzhong indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy AT ximian indoleamine23dioxygenase1andprogrammedcelldeathligand1coexpressionpredictspoorpathologicresponseandrecurrenceinesophagealsquamouscellcarcinomaafterneoadjuvantchemoradiotherapy |